Answers are grounded in this paper and cite their sources.
INTRODUCTION: Over the past 10 years, rapid molecular panels, point-of-care tests, host-response assays and sequencing have broadened and accelerated testing for pneumonia etiology. Yet detecting an organism remains different from showing that it caused disease, and more detections have not consistently improved patient outcomes. This review assesses what has changed in etiological diagnosis of pneumonia and where important uncertainties remain. AREAS COVERED: Developments in adult and pediatric community-acquired pneumonia, hospital-acquired and ventilator-associated pneumonia, and immunocompromised hosts are considered across syndromic molecular testing, clinical impact trials, host-response assays, sequencing and faster antimicrobial susceptibility testing. All specimens are considered, and conventional methods are discussed where they remain important to interpretation, treatment or surveillance. The evidence is assessed from detection through attribution and management to patient outcomes. EXPERT OPINION: Progress is clearest in speed and breadth of detection; gains in clinical decision-making are promising but selective, and better outcomes are not established consistently. The central problem remains: a positive test result does not necessarily indicate the cause of pneumonia. We also lack reliable answers about whom to test, which specimens best represent disease, how to interpret mixed findings, and which test-guided decisions are safe and beneficial. Technology has advanced faster than clinical validation.
No takes yet. Share an insight, caveat, or question.
David R. Murdoch (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: